PuraPharm Corporation Limited (PURAPHARM) has filed its Monthly Return for May 2026, confirming unchanged share capital and full compliance with Hong Kong’s public-float rules.

Authorised/Registered Capital • Authorised share capital remained at 5.00 billion USD, comprising 5.00 trillion ordinary shares with a par value of USD 0.001 each. No adjustments were recorded during the month.

Issued and Treasury Shares • Issued shares stood at 535.90 million, unchanged from April 2026. • The company held no treasury shares, and there were no share issues, cancellations, or repurchases. • PuraPharm confirmed adherence to the Main Board’s minimum 25% public-float threshold.

Equity Incentives • Outstanding options under the 12 June 2015 Share Option Scheme totalled 23.96 million, unchanged during the month. • No options were exercised, and no shares were issued or transferred from treasury. • Up to 31.79 million shares could still be issued under the scheme if future grants materialise.

Other Securities • The issuer reported no warrants, convertible securities, or other share-issuing agreements during the period.

Governance • The monthly return was submitted on 4 June 2026 by Company Secretary Charmayne Chan, reaffirming PuraPharm’s regulatory compliance and the stability of its capital structure for the month ended 31 May 2026.